BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38378431)

  • 1. SCGB2A2 as a predictor of prognosis and response to immune-checkpoint blockage in metastatic triple-negative invasive breast cancer.
    Zheng Y; Peng Y
    Asian J Surg; 2024 May; 47(5):2299-2301. PubMed ID: 38378431
    [No Abstract]   [Full Text] [Related]  

  • 2. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing an immune signature for triple-negative breast cancer to predict prognosis and immune checkpoint inhibitor response.
    Wang C; Feng G; Zhu J; Wei K; Huang C; Wu Z; Yu Y; Qin G
    Future Oncol; 2022 Mar; 18(9):1055-1066. PubMed ID: 35105171
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
    Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
    Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Checkpoint inhibitor therapy for metastatic triple-negative breast cancer.
    Heeke AL; Tan AR
    Cancer Metastasis Rev; 2021 Jun; 40(2):537-547. PubMed ID: 34101053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab and atezolizumab in triple-negative breast cancer.
    Kwapisz D
    Cancer Immunol Immunother; 2021 Mar; 70(3):607-617. PubMed ID: 33015734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MHC Class I Loss in Triple-negative Breast Cancer: A Potential Barrier to PD-1/PD-L1 Checkpoint Inhibitors.
    Dusenbery AC; Maniaci JL; Hillerson ND; Dill EA; Bullock TN; Mills AM
    Am J Surg Pathol; 2021 May; 45(5):701-707. PubMed ID: 33739790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Immunotherapy in Triple-Negative Breast Cancer.
    Keenan TE; Tolaney SM
    J Natl Compr Canc Netw; 2020 Apr; 18(4):479-489. PubMed ID: 32259782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-Checkpoint Inhibitors: A New Line of Attack in Triple-Negative Breast Cancer.
    Jarroudi OA; Bairi KE; Curigliano G; Afqir S
    Cancer Treat Res; 2023; 188():29-62. PubMed ID: 38175341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review).
    Li CJ; Lin LT; Hou MF; Chu PY
    Oncol Rep; 2021 Jan; 45(1):5-12. PubMed ID: 33416128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking.
    He R; Yuan X; Chen Z; Zheng Y
    Int Immunopharmacol; 2022 Dec; 113(Pt B):109444. PubMed ID: 36402069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer.
    Rizzo A; Cusmai A; Acquafredda S; Giovannelli F; Rinaldi L; Misino A; Palmiotti G
    Future Oncol; 2022 Jun; 18(18):2301-2309. PubMed ID: 35378995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
    Steiner M; Tan AR
    Clin Adv Hematol Oncol; 2021 May; 19(5):305-315. PubMed ID: 33989278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibition in early-stage triple-negative breast cancer.
    Varma R; Wright M; Abraham J; Kruse M
    Expert Rev Anticancer Ther; 2022 Nov; 22(11):1225-1238. PubMed ID: 36278877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
    Sivapiragasam A; Ashok Kumar P; Sokol ES; Albacker LA; Killian JK; Ramkissoon SH; Huang RSP; Severson EA; Brown CA; Danziger N; McGregor K; Ross JS
    Cancer Med; 2021 Jan; 10(1):53-61. PubMed ID: 33314633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.
    M-Rabet M; Cabaud O; Josselin E; Finetti P; Castellano R; Farina A; Agavnian-Couquiaud E; Saviane G; Collette Y; Viens P; Gonçalves A; Ginestier C; Charafe-Jauffret E; Birnbaum D; Olive D; Bertucci F; Lopez M
    Ann Oncol; 2017 Apr; 28(4):769-776. PubMed ID: 27998973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Platform Using a Triple-negative Breast Cancer Syngeneic Murine Model to Evaluate Immune Checkpoint Inhibitors.
    Katuwal NB; Park N; Pandey K; Kang MS; Hong SD; Ghosh M; Kim SG; Cho YB; Hur J; Kim SK; Moon YW
    Anticancer Res; 2023 Jan; 43(1):85-95. PubMed ID: 36585194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
    Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Mutational Burden and
    Barroso-Sousa R; Keenan TE; Pernas S; Exman P; Jain E; Garrido-Castro AC; Hughes M; Bychkovsky B; Umeton R; Files JL; Lindeman NI; MacConaill LE; Hodi FS; Krop IE; Dillon D; Winer EP; Wagle N; Lin NU; Mittendorf EA; Van Allen EM; Tolaney SM
    Clin Cancer Res; 2020 Jun; 26(11):2565-2572. PubMed ID: 32019858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of PD-L1 using SP142 CDx in triple negative breast cancer.
    Al-Jussani GN; Dabbagh TZ; Al-Rimawi D; Sughayer MA
    Ann Diagn Pathol; 2021 Apr; 51():151703. PubMed ID: 33454500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.